Trial Profile
A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Tresiba FlexTouch (Insulin Degludec) to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in Korea
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Apr 2020
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 27 Jun 2019 Status changed from recruiting to completed.
- 16 Jun 2016 Status changed from not yet recruiting to recruiting.
- 24 May 2016 New trial record